215 related articles for article (PubMed ID: 25400459)
21. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
22. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.
Chen ML; Wu CX; Zhang JB; Zhang H; Sun YD; Tian SL; Han JJ
Front Endocrinol (Lausanne); 2022; 13():996228. PubMed ID: 36187118
[TBL] [Abstract][Full Text] [Related]
23. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.
Ho CM; Lee CH; Lee MC; Zhang JF; Wang JY; Hu RH; Lee PH
BMC Cancer; 2018 Apr; 18(1):401. PubMed ID: 29631561
[TBL] [Abstract][Full Text] [Related]
25. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
26. Factors that affect risk for hepatocellular carcinoma and effects of surveillance.
Yang JD; Harmsen WS; Slettedahl SW; Chaiteerakij R; Enders FT; Therneau TM; Orsini L; Kim WR; Roberts LR
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):617-23.e1. PubMed ID: 21459158
[TBL] [Abstract][Full Text] [Related]
27. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.
Serper M; Taddei TH; Mehta R; D'Addeo K; Dai F; Aytaman A; Baytarian M; Fox R; Hunt K; Goldberg DS; Valderrama A; Kaplan DE;
Gastroenterology; 2017 Jun; 152(8):1954-1964. PubMed ID: 28283421
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
29. Clinical and prognostic implications of pretreatment albumin to C-reactive protein ratio in patients with hepatocellular carcinoma.
Wu MT; He SY; Chen SL; Li LF; He ZQ; Zhu YY; He X; Chen H
BMC Cancer; 2019 Jun; 19(1):538. PubMed ID: 31164099
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
Harris K; Smith L
Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
[TBL] [Abstract][Full Text] [Related]
31. Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Miyazaki T; Itagaki M; Sutoh S; Aizawa Y
World J Gastroenterol; 2013 Jan; 19(1):78-85. PubMed ID: 23326166
[TBL] [Abstract][Full Text] [Related]
32. Independent and Joint Use of Statins and Metformin by Elderly Patients With Diabetes and Overall Survival Following HCC Diagnosis.
Antwi SO; Li Z; Mody K; Roberts LR; Patel T
J Clin Gastroenterol; 2020; 54(5):468-476. PubMed ID: 32271517
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: a case-control study.
Li J; Huang L; Liu CF; Cao J; Yan JJ; Xu F; Wu MC; Yan YQ
World J Gastroenterol; 2014 Jul; 20(27):9121-7. PubMed ID: 25083085
[TBL] [Abstract][Full Text] [Related]
34. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies.
Chen HP; Shieh JJ; Chang CC; Chen TT; Lin JT; Wu MS; Lin JH; Wu CY
Gut; 2013 Apr; 62(4):606-15. PubMed ID: 22773548
[TBL] [Abstract][Full Text] [Related]
35. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
36. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
[TBL] [Abstract][Full Text] [Related]
37. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients.
Ruzzenente A; Capra F; Pachera S; Iacono C; Piccirillo G; Lunardi M; Pistoso S; Valdegamberi A; D'Onofrio M; Guglielmi A
J Gastrointest Surg; 2009 Jul; 13(7):1313-20. PubMed ID: 19418103
[TBL] [Abstract][Full Text] [Related]
38. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
[TBL] [Abstract][Full Text] [Related]
39. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A; Marisi G; Scarpi E; Scartozzi M; Faloppi L; Silvestris N; Masi G; Vivaldi C; Brunetti O; Tamberi S; Foschi FG; Tamburini E; Tenti E; Ricca Rosellini S; Ulivi P; Cascinu S; Nanni O; Frassineti GL
Expert Opin Pharmacother; 2015; 16(18):2719-25. PubMed ID: 26513009
[TBL] [Abstract][Full Text] [Related]
40. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
